Thursday, August 25th, 2022 - Perth, Australia: Biotome has been granted US Patent No. 11,401,308 covering the use of peptides that can detect CagA+ Helicobacter pylori infection for use in diagnostics.
Diagnostics using these peptides can identify individuals with carcinogenic CagA+ H. pylori infection, which is a major risk factor for developing stomach cancer. The patented peptides offer significant advantages over existing antigen-based methods as they target specific antibodies with high accuracy and sensitivity.
Tests for CagA+ H. pylori infection would help doctors more quickly and easily identify patients at increased risk of developing gastric cancer. Identifying and treating these infections greatly reduces a patient’s lifetime risk of developing stomach cancer and peptic ulcer disease.
“This is an important achievement as we work towards commercialization of our peptide-based diagnostic platform,” said CEO Samuel Lundin. “We believe these tests will make it easier for physicians to detect those individuals who are most at risk of developing life-threatening gastric cancers. This technology offers great promise in reducing the global burden of gastric cancer which claims hundreds of thousands of lives each year.”
AI interpretation of specific antibodies selectively attaching to a peptide (OpenAI / Dalle-2).
“Securing patents for our diagnostic peptides is a fundamental advantage of our technology. IP protection is a challenge for traditional antigen-based diagnostics,” said Luke Marshall, Head of Business Development. “This greatly strengthens our position in future partnerships and licensing deals.”
Thanks to this new patent, Biotome is one step closer to making this life saving technology available around the world.